BACKGROUND: Previous research suggests that the G315A single-nucleotide polymorphism in the ornithine decarboxylase (ODC) gene may be a genetic marker for risk of colorectal neoplasia and may also modify the association of aspirin use with risk. METHODS: We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned toplacebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas. Genomic DNA from 973 subjects was analyzed for ODC genotype. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated to test the association between ODC genotype and adenoma occurrence and interactions with aspirin treatment. All statistical tests were two-sided. RESULTS: Of the 973 subjects, 54% were homozygous wild-type (GG), 7% were homozygous variant (AA), and 39% were heterozygous individuals; the allele frequencies varied statistically significantly by race and ethnicity. Among these subjects, the absolute risk of any adenoma was 45% and the risk of an advanced lesion was 10%. Overall, no association was found between ODC genotype and the occurrence of new adenomas, but genotype did modify the effect of aspirin on adenoma risk. Although aspirin treatment had no protective effect among subjects with a GG genotype, among subjects with at least one A allele, it was associated with statistically significant reduced risks of any adenoma (RR = 0.77, 95% CI = 0.63 to 0.95; P = .02, P(interaction) = .04) and of advanced lesions (RR = 0.51, 95% CI = 0.29 to 0.90; P = .02, P(interaction) = .02). Among subjects with at least one A allele, 40.8% who took aspirin versus 52.9% who took placebo developed adenomas; 7.1% versus 14.0% developed advanced lesions. CONCLUSION: ODC genotype may modify the response to aspirin treatment for colorectal adenoma prevention.
RCT Entities:
BACKGROUND: Previous research suggests that the G315A single-nucleotide polymorphism in the ornithine decarboxylase (ODC) gene may be a genetic marker for risk of colorectal neoplasia and may also modify the association of aspirin use with risk. METHODS: We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas. Genomic DNA from 973 subjects was analyzed for ODC genotype. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated to test the association between ODC genotype and adenoma occurrence and interactions with aspirin treatment. All statistical tests were two-sided. RESULTS: Of the 973 subjects, 54% were homozygous wild-type (GG), 7% were homozygous variant (AA), and 39% were heterozygous individuals; the allele frequencies varied statistically significantly by race and ethnicity. Among these subjects, the absolute risk of any adenoma was 45% and the risk of an advanced lesion was 10%. Overall, no association was found between ODC genotype and the occurrence of new adenomas, but genotype did modify the effect of aspirin on adenoma risk. Although aspirin treatment had no protective effect among subjects with a GG genotype, among subjects with at least one A allele, it was associated with statistically significant reduced risks of any adenoma (RR = 0.77, 95% CI = 0.63 to 0.95; P = .02, P(interaction) = .04) and of advanced lesions (RR = 0.51, 95% CI = 0.29 to 0.90; P = .02, P(interaction) = .02). Among subjects with at least one A allele, 40.8% who took aspirin versus 52.9% who took placebo developed adenomas; 7.1% versus 14.0% developed advanced lesions. CONCLUSION:ODC genotype may modify the response to aspirin treatment for colorectal adenoma prevention.
Authors: Ashley J Vargas; Betsy C Wertheim; Eugene W Gerner; Cynthia A Thomson; Cheryl L Rock; Patricia A Thompson Journal: Am J Clin Nutr Date: 2012-05-30 Impact factor: 7.045
Authors: Jason A Zell; Argyrios Ziogas; Natalia Ignatenko; Jane Honda; Ning Qu; Alexander S Bobbs; Susan L Neuhausen; Eugene W Gerner; Hoda Anton-Culver Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Elizabeth L Barry; Leah B Sansbury; Maria V Grau; Iqbal U Ali; Shirley Tsang; David J Munroe; Dennis J Ahnen; Robert S Sandler; Fred Saibil; Jiang Gui; Robert S Bresalier; Gail E McKeown-Eyssen; Carol Burke; John A Baron Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-09-15 Impact factor: 4.254